New Study Identifies Inflammatory Proteins Driving JMML Progression

Recent research funded by Alex’s Lemonade Stand Foundation at Indiana University has identified specific inflammatory proteins that contribute to the progression of juvenile myelomonocytic leukemia (JMML), a rare blood cancer in children.

JMML is known for its aggressive nature and primarily affects young children. Standard treatment often involves stem cell transplantation, but only about half of patients achieve a cure, with relapse remaining the most common cause of death.

Researchers discovered that the inflammatory proteins PTX3 and IL-15 are present at higher levels in JMML. These proteins were found to suppress the activation of cytotoxic T-cells, which are important for immune defense, while also promoting the growth of leukemia cells.

To further study these effects, scientists developed new genetically engineered mouse models that mimic the disease. These models confirmed that blocking PTX3 and IL-15 reduces immune suppression and lessens the severity of JMML symptoms.

What the numbers show

• About 50% of JMML patients are cured by stem cell transplantation
• Relapse is the leading cause of death in JMML cases
• Approximately 35% of JMML cases involve PTPN11 gene mutations

In experiments using these mouse models, researchers tested the effects of blocking PTX3 and IL-15, both alone and in combination with a MEK inhibitor. The results showed reduced leukemia symptoms, restored normal immune cell function, and improved survival rates without major side effects.

JMML is also characterized by a hyperinflammatory state, which involves increased activity of innate immune cells and heightened sensitivity to the growth factor GM-CSF. This inflammatory environment is believed to play a role in disease progression and relapse.

The findings suggest that targeting inflammatory pathways, specifically PTX3 and IL-15, may offer new strategies for managing JMML. The study highlights the importance of understanding the molecular mechanisms that drive immune suppression and leukemia cell growth in this rare pediatric cancer.

Further research is expected to build on these results and explore potential clinical applications for therapies that block these inflammatory proteins in JMML patients.

* This article is based on publicly available information at the time of writing.